Webinar: Fill-Finish for Viral Vector Production

More than ever, patient-centered therapeutics require technologies designed for maximizing yield that improve product safety and efficacy, and reduce overall processing time.  Advancements like accelerated decontamination cycle times and 100 percent IPC with no compromise to production speed offer pharmaceutical manufacturers greater flexibility and faster time-to-patient.

Get an in-depth look at an isolated fill-finish system built for viral vector production, placed with a global cell and gene therapy CDMO. The isolated GENiSYS C was designed to be a robust Annex 1 solution, outfitted with zero-waste technologies and product stewardship measures for optimized hand-free production of advanced therapeutics. 

Fill out the form below to access the webinar: